Recent Research Analysts’ Ratings Changes for Stryker (SYK)

Posted by Steve Fairfield on Jan 28th, 2025

A number of research firms have changed their ratings and price targets for Stryker (NYSE: SYK):

1/22/2025 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
1/9/2025 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
1/7/2025 – Stryker had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $425.00 price target on the stock.
1/7/2025 – Stryker had its “market perform” rating reaffirmed by analysts at JMP Securities.
1/7/2025 – Stryker had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $442.00 price target on the stock.
1/1/2025 – Stryker was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
12/18/2024 – Stryker had its price target raised by analysts at Truist Financial Co. from $380.00 to $409.00. They now have a “hold” rating on the stock.
12/12/2024 – Stryker had its price target raised by analysts at Needham & Company LLC from $409.00 to $442.00. They now have a “buy” rating on the stock.
12/11/2024 – Stryker had its price target raised by analysts at Wells Fargo & Company from $405.00 to $427.00. They now have an “overweight” rating on the stock.
12/11/2024 – Stryker had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $425.00 price target on the stock, up previously from $400.00.
12/11/2024 – Stryker was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
12/11/2024 – Stryker had its price target raised by analysts at Citigroup Inc. from $411.00 to $450.00. They now have a “buy” rating on the stock.
12/2/2024 – Stryker was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $445.00 price target on the stock, up previously from $370.00.

Stryker Trading Down 0.7 %

SYK traded down $2.98 on Tuesday, reaching $396.92. 1,018,933 shares of the company’s stock were exchanged, compared to its average volume of 1,437,758. Stryker Co. has a twelve month low of $310.74 and a twelve month high of $406.19. The company’s 50 day moving average is $376.32 and its 200-day moving average is $361.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market cap of $151.31 billion, a price-to-earnings ratio of 42.54, a PEG ratio of 2.68 and a beta of 0.95.

Stryker (NYSE:SYK – Get Free Report) last announced its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the previous year, the company earned $2.46 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Equities analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

Several institutional investors have recently modified their holdings of SYK. Dunhill Financial LLC boosted its position in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Centennial Bank AR raised its stake in shares of Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in Stryker in the third quarter worth about $36,000. Crews Bank & Trust bought a new position in Stryker in the 4th quarter valued at about $39,000. Finally, Hara Capital LLC acquired a new position in Stryker during the 3rd quarter valued at about $42,000. Institutional investors own 77.09% of the company’s stock.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.